SynBiotic (SCALE: SBX)

Last close As at 22/02/2024

EUR9.78

2.02 (26.03%)

Market capitalisation

EUR46m

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

View More

Consumer | Outlook

SynBiotic — Building the platform

Consumer | Update

SynBiotic — Management update – on track

Consumer | Update

SynBiotic — Further acquisitions

Consumer | QuickView

SynBiotic — Building a cannabis platform

Sector

Consumer

Equity Analyst

Russell Pointon

Russell Pointon

Director, Consumer

Key Management

  • Daniel Kruse

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 184.302 234.931 (10.541)
Relative 174.952 211.108 (19.532)
52 week high/low €10.8/€2.9

Financials

SynBiotic’s management has created a platform that spans the value chain in the cannabis and cannabinoid space, from cultivation and labs to distribution. SynBiotic’s business creates and markets cannabis and cannabinoid products, which have both medical and consumer applications, with management constantly looking to add to its portfolio. We believe SynBiotic is well-placed to benefit from any relaxation in legislation around cannabis and cannabinoid products in Germany, as per the published government white paper (Eckpunktepapier), as it already operates across the cannabis value chain and has expertise in the field.

Research

QuickView

Consumer

SynBiotic — Building a cannabis platform

Initiation

Consumer

SynBiotic — Working together

Thematics

thematic

Consumer

ConsumerWatch – October 2023

thematic

Consumer

ConsumerWatch – July 2023

thematic

Consumer

ConsumerWatch – April 2023

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free